Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05797168 · ClinicalTrials.gov registry record · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 506
- Enrollment target
- 20
- Study locations
NCT05797168: Recruiting Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by AstraZeneca.
NCT05797168 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 506 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05797168, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 506 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Primary Outcome
Number of participants with incidence of adverse events and with serious adverse events including changes from baseline in laboratory parameters, vital signs, ECGs, and physical examination.
Conditions Studied
Interventions
- DRUG AZD5335
- DRUG Saruparib (AZD5305)
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG AZD9574
Study Locations (20)
California
- Research Site - Duarte
- Research Site - Irvine
- Research Site - La Jolla
Rhode Island
- Research Site - Providence
- Research Site - Providence
Other
- Research Site - Liverpool
- Research Site - Melbourne
Ontario
- Research Site - London
- Research Site - Toronto
Quebec
- Research Site - Montreal
- Research Site - Montreal
Colorado
- Research Site - Aurora
Kentucky
- Research Site - Louisville
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2023-06-05 |
| Est. Completion | 2028-01-06 |
| Phase | Phase 1 |
What NCT05797168 shows while recruiting
NCT05797168 is an interventional study that assigns participants to a tested intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (30% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which AZD5335 is the first listed.
NCT05797168 names 20 study sites across 14 states, led by California, Rhode Island, Other.
Frequently Asked Questions
What is clinical trial NCT05797168 about?
NCT05797168 is a clinical study titled "Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors". This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
What is the current status of trial NCT05797168?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 506 participants. The study started on 2023-06-05. Estimated completion is 2028-01-06.
What conditions does trial NCT05797168 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Lung Adenocarcinoma.
What interventions are being tested in trial NCT05797168?
The interventions under investigation include: AZD5335 (DRUG), Saruparib (AZD5305) (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), AZD9574 (DRUG).
Who is sponsoring clinical trial NCT05797168?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05797168 being conducted?
This trial has 20 study locations across California, Colorado, Kentucky, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05797168's enrollment target sits among peer trials
506 48th of 322 higher than 275 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI